ACE-031 is one of the myostatin-pathway drugs that appear in muscle-growth discussions. It is a protein, not a small peptide, and the human record is small. Most of what is written about it online comes from its mechanism, not from a trial.
The first-screen answer
| Study | Who | Dose | Length | What was measured |
|---|---|---|---|---|
| Attie et al., 2013 | 48 healthy postmenopausal women, randomised 3:1 to drug or placebo | One dose, 0.02 to 3 mg/kg | 29 days | Lean mass +3.3% and thigh muscle volume +5.1% in the 3 mg/kg group |
| Campbell et al., 2017 | Ambulatory boys with Duchenne muscular dystrophy | Repeated doses every 2 to 4 weeks | Stopped after second regimen | Safety stop for nosebleeds; non-significant trends in walking and lean mass |
| Cadena et al., 2026 | Common marmosets, randomised to drug or vehicle | Not stated in the abstract | 14 weeks | Lean mass up against baseline; biceps fibre area and EDL force up |
Only the first study is a placebo-controlled human trial of healthy people, and it measured one dose for a month. The second was stopped early in a different population. The third is an animal study.
The single-dose study in healthy women
The 2013 study gave one subcutaneous dose of ACE-031, at doses from 0.02 to 3 mg/kg, to 48 healthy postmenopausal women, with placebo in a 3:1 ratio. The drug was generally well tolerated, and the only adverse event named in the abstract was injection-site redness. Its half-life was 10 to 15 days. At day 29, the 3 mg/kg group's whole-body lean mass by DXA was 3.3% above baseline, and thigh muscle volume by MRI was 5.1% above, both reported as P = 0.03. The size of each dose group and the strength data are in the full paper, which this page did not extract. The study ran for one month and measured no strength or function outcome.
The boys' trial, stopped for bleeding
The 2017 trial gave ACE-031 to ambulatory boys with Duchenne muscular dystrophy, randomised against placebo, and its primary objective was safety. The study was stopped after the second dosing regimen because of concern about nosebleeds and telangiectasias. The authors say the non-muscle adverse events contributed to that decision. They report trends toward a smaller decline in six-minute walk distance, more lean mass and bone density, and less fat mass in the ACE-031 groups, and state that none of the trends reached statistical significance. The authors' own conclusion rests on those trends being non-significant and on the safety stop.
The marmoset study
In a 14-week randomised study in common marmosets, the ACE-031 group's lean body mass was higher at the end than at the start, a change the vehicle group did not show. Biceps fibre cross-sections grew in both fibre types, and the extensor digitorum longus muscle produced more force. Marmosets are not humans, and the study reports no human dose.
Products sold online
A 2025 laboratory study tested 14 products sold as ACE-031 on the black market. Twelve reacted with an antibody to the activin receptor, which is what a crude test would pick up. Mass spectrometry identified full-length human activin receptor IIB in those products, not the fusion protein that defines ACE-031, and a protease that cuts the fusion protein did not cut them. The authors also gave a rat dose of 10 mg/kg and detected the product in serum up to 48 hours later, a detection window they say may differ in people. The study tested the products its authors obtained; it does not show what any vendor sells now.
Status in sport and as a medicine
The authors of the 2025 study report that ACE-031 has not been pharmaceutically approved. WADA places agents that prevent activin receptor IIB activation in section S4.3, which is prohibited at all times. A related compound, follistatin, is on the same list; see follistatin for how its human evidence compares. The drug-testing rules that apply to sport are on peptides and drug testing.
What is not established
- Whether ACE-031 raises strength, walking, or independence in adults. No human trial has measured those outcomes in a study designed for them.
- Whether the 2013 lean-mass gain persists or changes muscle quality rather than DXA-measured lean tissue.
- What the long-term safety profile is, given the bleeding findings in the 2017 trial.
- Whether any product sold online contains ACE-031 at all. The one sample study found it did not, for the products it tested.
Where the evidence sits on this site
The wider evidence for myostatin-pathway agents, including what is and is not established for muscle growth in healthy adults, is on peptides for muscle growth. This page covers only the compound itself.
Sources and dates
- Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423. PubMed 23169607. Opened 2026-11-09.
- Campbell C, McMillan HJ, Mah JK, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy. Muscle Nerve. 2017;55(4):458-464. PubMed 27462804. Opened 2026-11-09.
- Cadena SM, Bogdanovich S, Khurana TS, et al. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset. PLoS One. 2026;21(2):e0342666. PubMed 41686840. Opened 2026-11-09.
- Reichel C, Filip T, Gmeiner G, Thevis M. Gel electrophoretic detection of black market ACE-031. Drug Test Anal. 2025;17(10):1934-1946. PubMed 40312924. Opened 2026-11-09.
- All four were read from PubMed abstracts. Sample sizes, dose ranges and statistical values are as printed in those abstracts; full texts were not extracted for this page.
